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ABSTRACT
The RFLP/PCR approach (restriction fragment length
polymorphism/polymerase chain reaction) to genotypic
mutation analysis described here measures mutations
in restriction recognition sequences. Wild-type DNA is
restricted before the resistant, mutated sequences are
amplified by PCR and cloned. We tested the capacity
of this experimental design to isolate a few copies of
a mutated sequence of the human c-Ha-rasl gene from
a large excess of wild-type DNA. For this purpose we
constructed a 272 bp fragment with 2 mutations in the
Pvull recognition sequence 1727-1732 and studied the
rescue by RFLP/PCR of a few copies of this 'Pvull
mutant standard'. Following amplification with Taq-
polymerase and cloning into XgtlO, plaques containing
wild-type sequence, Pvull mutant standard or Taq-
polymerase induced bp changes were quantitated by
hybridization with specific oligonucleotide probes. Our
results indicate that 10 Pvull mutant standard copies
can be rescued from 108to 109 wild-type sequences.
Taq polymerase errors originating from unrestricted,
residual wild-type DNA were sequence dependent and
consisted mostly of transversions originating at G.C bp.
In contrast to a doubly mutated 'standard' the capacity
to rescue single bp mutations by RFLP/PCR is limited
by Taq-polymerase errors. Therefore, we assessed the
capacity of our protocol to isolate a G to T transversion
mutation at base pair 1698 of the MspI-site 1695 - 1698
of the c-Ha-rasl gene from excess wild-type rasl DNA.
We found that 100 copies of the mutated rasl fragment
could be readily rescued from 108 copies of wild-type
DNA.
INTRODUCTION
Molecular characterization and quantitation of mutations is of
fundamental importance to the understanding of evolution,
differentiation and the etiology of hereditary disease. The frequent
occurrence of single base pair changes in the activation of the
ras protooncogenes (1) and in the inactivation of the tumor
suppressor gene p53 (2-4) documents the involvement of
mutations in human carcinogenesis. Ideally, methods are required
which allow it to identify specific DNA sequence changes in
relevant genes in tissue biopsies. For the elucidation of early
pathogenetic processes it is necessary to detect these changes in
a minute minority of cells without the clonal expansion of mutated
cells in vivo or in vitro and without the need for the expression
of a selectable mutant phenotype (5). To achieve this goal it is
necessary to isolate specific mutated DNA sequences from a large
excess of homologous wild type DNA by biochemical means.
In contrast, all classical 'phenotypic' mutation systems rely on
the isolation of a few mutated cells from a large, usually dividing
cell population. This limits mutation analysis to a few genes
encoding proteins which produce a selectable cellular phenotype.
A number of experimental approaches to 'genotypic' mutation
systems have been developed (6). Several are based on Southern-
or Northern hybridization often with sequence amplification by
polymerase chain reaction (PCR) and in combination with the
specific cleavage of hetero-duplexes at mismatched base pairs.
Other protocols take advantage of differences in electrophoretic
mobilities of hetero-duplexes or of mutated single stranded nucleic
acids. The sensitivity of all these approaches are limited by
backgrounds which arise from the presence of excess wild-type
sequences. The RFLP/PCR approach to genotypic mutation
analysis described here greatly reduces this problem. Base-pair
(bp) mutations are detected which are located in a restriction
recognition sequence and render this site resistant to cleavage
by the corresponding endonuclease. The resistant DNA sequence
containing the mutated site is amplified by PCR only after wild
tpe DNA has been essentially eliminated by restriction digestion.
Amplified DNA is cloned into XgtlO and mutants are quantitated
by oligonucleotide plaque hybridization relative to an internal
standard. The maximal sensitivity of the RFLP/PCR method is
determined by the completeness of the removal of wild-type
sequences together with the inherent error-rate at a particular base
pair of the polymerase used in the PCR. The RFLP/PCR protocol
for genotypic mutation analysis is applicable to any gene ofknown
sequence. It is highly sensitive, but limited to the identification
of point mutations (bp-changes, small deletions and insertions)
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which result in the elimination of restriction sites. We report here
results involving bp-changes in the PvuII site 1727- 1732 and
the MspI site 1695 - 1698 of exon 1 of the human c-Ha-rasl gene.
The MspI-site 1695-1698 covers 2 bp of codon 12 of c-ras which
represents a mutation hot spot in human cancer (1).
METHODS
RFLP/PCR analysis of PvuII-site 1727-1732 of c-Ha-rasl
Preparation of authentic mutants at PvuII-site 1727-1732 of c-
Ha-ras]. All 12 possible single bp mutations in the internal
tetranucleotide AGCT of the Pvull recognition sequence (residues
1727- 1732) of exon 1 of the human c-Ha-rasl gene were
prepared using synthetic oligonuleotides and a PCR protocol (see
Figure 1 for sequence information). Twelve different 20-mers
corresponding to residues 1719-1738 which contained single
base changes in the AGCT sequence were used as left-side
amplimers. A common right-side amplimer corresponding to
nucleotides 1765-1784 of c-Ha-rasl plus a 12 nucleotide tail
containing an EcoRI recognition-sequence was used in 12 PCR
reactions with pSVneo-rasl as template (note: pSVneo-ras 1
contains the BamHI fragment, residues 1-6453, of human c-
Ha-rasl (7) inserted into the BamHI sites of the SVneo cloning
vector). The amplification conditions were as described below.
The 12 resulting 78 bp fragments were purified on Quiagen-5
tips as described by the supplier (DIAGEN, KONTRON,
Switzerland) and then used as right-side amplimers in a second
round of amplifications with a common left-side amplimer
corresponding to residues 1646-1665 of c-Ha-rasl plus a 12
nucleotide tail containing an EcoRI recognition sequence. The
resulting 163 bp fragments were purified on Quiagen-5 tips,
digested with EcoRI and cloned into XgtlO.
All authentic mutant XgtlO constructs were plaque purified on
E. coli C600 Hfl. For this purpose plaques were lifted onto
colony/plaque screens and probed with mutant specific 32P-end-
labeled oligonucleotides. Positive plaques were picked, the phage
eluted from the agar and plated onto E. coli C600 Hfl. When
confluent lysis had been achieved the phage was collected in Sml
buffer (1OOmM NaCl, 20 mM Tris.HCl pH 7.4, lOmM
MgSO4) and after the addition of 100 Al CHCl3 the suspension
was centrifuged at 10'000 rpm for 10 min at 4°C. Mutant phage
contained in the supernatant was titered and then stored at 4°C
in the presence of 0.3% CHCl3.
A mutant standard with two bp changes in the Pvull recognition
sequence and an additional upstream mutation was prepared
according to the same experimental design using the 20-mer 5'T-
GAGCATCCTGGTGATCCAG (residues 1719-1738 of c-Ha-
rasI; positions of mutations underlined) as left-side amplimer and
a 20-mer corresponding to the sequence from residue 1888 to
1907 of c-Ha-rasl as right-side amplimer. The right-side
amplimer contains a XbaI recognition site. The amplification
conditions were as described below except that the DMSO
concentration was only 6%. After 38 cycles the resulting 188
bp fragment was purified on a Quiagen-5 tip and used as right-
side amplimer in a second amplification reaction with a left-side
amplimer corresponding to residues 1636 to 1655 of c-Ha-rasl
which contains a SmaI site. After purification the final 272 bp
fragment was digested with XbaI and SmaI and cloned into
pSP64. This plasmid, referred to as 'mutant standard' (pSP64-ras
PvuIISt), was used as internal standard in mixtures with
pSVneo-ras 1.
PvII - restriction and amplification. A stock of pSVneo-ras 1 was
digested exhaustively with 4U PvuII/itg plasmid DNA in Tris
buffer pH 7.5, 10mM MgCl2, 50mM NaCl, 1mM DTE for 3
h at 37°C. To 108 copies of restricted pSVneo-rasl was added
10 or 100 copies of PvuII mutant standard (see above) which
had been predigested with XbaI and SmaI in order to release a
272 bp fragment containing the mutated sequence. The samples
were prepared in the amplification buffer which was composed
of 66.7mM Tris.HCl pH 8.8 (25°C), 6.7mM MgCl2, 16.6mM
(NH4)2SO4, 1mM each of the 4 dNTPs, 12% DMSO, 1.25 AM
of the left-side and right-side amplimers in a final volume of 25
tld. The amplimers used in the first 30 PCR cycles were 20-mers
corresponding to the sequences 1646- 1665 and 1765- 1784 of
c-Ha-rasl (see Figure 1). After addition of 0.5 U of Taq
polymerase (from bact. Thermus aquaticus, Cetus, Calif.) the
samples were heated initially to 91 °C for 4 min followed by 95
sec at 59'C. Consecutive cycles consisted of 85 sec at 91 'C and
95 sec at 59°C and were carried out in an Ampligene Apparatus,
Moretronic, Switzerland. After 2,4,6 and 8 cycles 1 U PvuII
was added and the samples incubated for 10 min at 52°C in order
to eliminate any amplified wt-sequence. Amplification was then
continued with 0.5 U fresh Taq-polymerase. After the first 8
cycles the amplification was continued without interruption up
to 30 cycles when a 1 Al aliquot was withdrawn from each sample
and added to 50 A1 fresh amplification buffer. The mixtures
contained 1.6 AM of clonable amplimers which in addition to
the 20-mer sequences described above contained a 12-nucleotide
tail with an EcoRI-recognition sequence (see Figure 1). Before
the continuation of the amplification for 10 cycles the samples
were treated with Pvull for 20 min at 37°C. In independent
experiments 109 copies of PvuII digested pSVneo-rasl were
mixed with 1 or 1000 copies of mutant standard and processed
according to the protocol described above except that PvuII
digestions during amplification were omitted.
Purification of amplified DNA and cloning into XgtlO. The
amplification mixtures were purified on Quiagen-5 tips and the
DNA precipitated with isopropanol after the addition of 1 Ag E.
coli tRNA as carrier. The samples were then treated with EcoRI
in order to free the ends of the amplified fragment. After renewed
purification on Quiagen-5 tips, precipitation with isopropanol and
washing of the precipitates with 75 % ethanol Sng/DNA aliquots
were ligated to 500 ng XgtlO arms as outlined by the supplier
(Promega Biotec, Madison, WI.) The phage DNA was packaged
(Packagener, Promega Biotec, Madison, WI.) and E. coli C600
Hfl infected. Plaques were lifted onto colony/plaque screens
(NEF-978, New England Nuclear). At least 2 independent
packagings were carried out and 1-3 x 103 plaques on 10 to 15
Petri-dishes were analyzed for each experimental condition.
Oligonucleotide plaque hybridization. Specific probes were
prepared according to standard conditions by end-labeling with
gamma-32P-ATP with T4 polynucleotide kinase of
oligonucleotide 20-mers corresponding to the wild-type sequence
1719-1738 of c-Ha-rasl, mutant standard containing 3 base
changes and oligomers containing all 12 possible single base
mutations in the internal tetranucleotide AGCT of PvuII
recognition site 1727-1732. The colony/plaque screens to be
analyzed were prehybridized for 1 h with 5 x SSPE (1 x: lOmM
Na-phosphate pH 7.4, 1mM EDTA, 0.l5M NaCl), 0.3 % SDS,
1% milk protein. After rinsing with water the discs were
hybridized overnight with the radioactive probes at 54°C in
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5 x SSPE, 0.3% SDS. After a first wash at room-temperature
with 5 x SSPE selective washing temperatures between 60 and
63°C were employed in order to exclude non-specific
hybridization. The selective washing temperatures were
determined with known mixtures of XgtlO stocks containing
authentic mutant inserts (for their preparation see above).
RFLP/PCR analysis of MspI-site 1695-1698 of c-Ha-rasl
Preparation ofauthentic mutant rasl-Ti698 with a single base
pair substituion in the MspI-site 1695-1698. The c-Ha-rasl gene
with a G-T transversion at residue 1698 of exon 1 had been
originally cloned from the EJ human bladder carcinoma line (8).
A SmaI fragment (1644-2246) of this gene was cloned into the
vector puc 8. From this the XbaI-EcoRI ras fragment 1644-1905
was removed and cloned into the pSP64 vector (9). This vector,
referred to below as pSP64-rasl-T1698 was used in the mutant
rescue experiments described below.
MspI/HpaII-restriction and amplification. Stocks ofpSVneo-rasl
were digested exhaustively with lOU MspI/Lg and 2U Hpall/ug
plasmid overnight at 370 under the conditions described above
for Pvul. pSP64-rasl-T1698 was digested with XbaI-EcoRI in
order to release a 261 bp fragment containing the mutated MspI-
site 1695-1698 CCGT. Three samples were prepared in the
amplification buffer described above except that the DMSO
concentration was only 6%: a) 108 copies restricted pSVneo-
rasl b) 100 copies restricted pSP64-rasl-T1698 plus 108 copies
restricted pSVneo-rasl c) 1000 copies restricted
pSP64-rasl-T1698 plus 108 copies restricted pSVneo-rasl. The
amplimers used in the first 35 PCR cycles were 20-mers
corresponding to the sequences 1646-1665 and 1765- 1784 of
c-Ha-rasl (see Figure 1). The amplification cycles were as
described above. After 2,4,6,8,10,12 and 14 cycles 2U MspI
were added and the samples incubated for 10 mi at 55°in order
to eliminate any residual wild-type sequences. Amplification was
then continued after the addition of O.5U fresh Taq polymerase.
After 14 cycles the amplification was continued to 35 cycles
without interruption when a 11 aliquot was withdrawn from each
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sample and added to 50,ul fresh amplification buffer. The
amplification was continued with 1.6uM nested clonable left-side
amplimer 1673-1692 and clonable right-side amplimer
1765-1784. These amplimers possessed 12-nucleotide 5'-tails
containing EcoRI-recognition sequences (see Figure 1). All
subsequent steps consisting of purification of the amplified DNA,
cloning into XgtlO and oligonucleotide plaque hybridization were
as described above for the analysis of mutants in the Pvull-site
1727-1732. The results shown on Figure 5 are derived from
2 independent packagings and 600-1100 plaques on 4 to 6 Petri
dishes.
Radiolabeled amplimer incorporation
In order to compare the efficiency of amplification of mutant
standard and wild-type c-Ha-rasl DNA the 20-mer corresponding
to residues 1646-1665 was end-labeled witi y-32P-ATP and T4
polynucleotide kinase under standard conditions. This
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Figure 1. Sequence 1646-1784 of exon 1 of human c-Ha-rasl. The MspI
recognition site 1695-1698 and the Pvull recognition site 1727-1732 used in
the RFLP/PCR experiments are marked. The sequences of the single base pair
mutant pSP64-rasl-T1698 in the MspI-site 1695-1698 and of the Pvul mutant
standard SP64-ras-PvuIISt are given in the lower part of the Figure. Only the
sequences of the 'clonable' amplimers with 5'-tails containing EcoRI recognition
sites are shown.
29 cycles 34 cycles
Figure 2. Comparison of amplification efficiencies of the wild-type c-Ha-rasl
sequence 1646-1784 and of the corresponding PvnI mutant standard sequence.
A. Incorporation of 5'-32P_endlabeled left-side amplimer into 138bp amplified
fragment with Taq-polymerase. Aliquots were withdrawn at increasing numbers
of PCR-cycles and applied on 5% polyacrylaiide gels for electWphoretic analysis.
The dried gels were exposed to x-ray film for autoradiography and the intensity
of the bands at 138bp determined by densitometry. X--X and [1-[1, 5 x 1010
and 108 copies of Xbal/SmaI digested wild-tyr pSVneo-ras were used as
template, respectively; A-A and U-U, 5 x 101° and 10i copies of XbaI/SmaI
digested mutant standard pSP64-ras PvuIISt were used as template, respectively
(see 'Methods'). B. Fonnation of 138bp sequence 1646-1784 by amplification
with Taq-polymerase of 105, 103 and 10 copies of XbaI/SmaI-digested wild-type
pSVneo-ras or mutant standard pSP64-ras PvullISt as templates. After the indicated
numbers of PCR- cycles aliquots of the reaction mixtures were electrophoresed
on 2% agarose gels and the 138bp band visualized by ethidiumbromide staining
(see 'Methods').
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radiolabeled oligonucleotide was used as left-side amplimer in
a PCR-reaction with a non-radioactive right-side amplimer and
5 x 1010 copies of XbaI and SmaI digested mutant standard
pSP64-ras PvuIISt or of XbaI and SmaI digested pSVneo-rasl
as templates, respectively. In a second experiment only 108
copies of the template DNAs were used. Amplification conditions
were as described above with the exception that no PvuII
digestions were performed. Aliquots of the reaction mixtures were
withdrawn after increasing numbers of PCR cycles and applied
to 5% polyacrylamide gels. After development, the dried gels
were exposed to x-ray film for autoradiography. The intensities
of the bands at 138 bp corresponding to the expected amplification
product were determined by densitometry (Zeineth Scanning
densitometer, Biomed Instr., CA.).
RESULTS
Efficiency of amplification of PvuII mutant standard and
wild-type sequence 1646-1784 of c-Ha-rasl
In order to calibrate single bp mutations by RFLP/PCR an internal
'PvuII mutant standard' is used with 2 bp-mutations in the chosen
recognition sequence. We prepared a mutant standard pSP64-ras
PvuIISt with 2 bp changes in the PvuII recognition sequence
(1727-1732) and an additional mutation upstream (see Methods
and Fig. 1). For the validity of the calibration the amplification
efficiencies for mutant standard DNA and mutated sequences (or
undigested wt-sequences) from genomic DNA have to be the
same. This is demonstrated in Figure 2. The upper portion shows
that radiolabeled left-side amplimer (see Figure 1 for sequences)
was incorporated into the desired 138 bp fragment with equal
efficiency whether mutant standard or wt-sequence served as
template. Either 5 x 1010 or 108 initial copies of the templates
were amplified for 10 or 14 PCR cycles, respectively.The lower
portion of Figure 2 compares the amounts of 138 bp fragment
synthesized from 105, 103 and 10 copies of the two templates
after 29 and 34 PCR cycles directly by ethidiumbromide staining
on a 2% agarose gel. The results indicate comparable
amplification efficiencies for PvuII mutant standard- and wt-
template also at low numbers of initial copies and high cycle
numbers.
Rescue of Pvull mutant standard from excess wild-type
sequence 1646-1784 of c-Ha-rasl
The capability of the RFLP/PCR method to rescue a small
number of copies of Pvull mutant standard from a large excess
of wt sequence was investigated. Mixtures were prepared of 10
and 100 copies of XbaI/SmaI digested mutant standard pSP64-ras
PvuIISt with 108 copies of exhaustively Pvull digested pSVneo-
rasl and of 1000 copies of mutant standard with 109 copies
Pvull digested pSVneo-rasl. The mutant standard was restricted
with XbaI/SmaI in order to release a 272 bp fragment similar
in size to the 256 bp ras-fragment which is liberated by PvuII
from pSVneo-rasl containing a mutation in the PvuII site
1727-1732. The mixtures were amplified with repeated
restrictions with Pvull in 30 cycles with 'non-clonable' amplimers
and 10 final cycles with amplimers containing tails with EcoRI
recognition sequences (see 'Methods' and Figure 1). The 163bp
amplified fragments were cloned into XgtlO and plaques were
analyzed by oligonucleotide hybridization for their content in wt
rasl sequence 1719-1738 and mutant standard sequence.
The results summarized in Table 1 show that as few as 10
copies of PvuII mutant standard were rescued from 108 copies
ANALYSIS OF AMPLIFICATION MIXTURE
BY k -PLAQUE HYBRIDIZATION *
Mutant standard Wild type Mutant standard WildtplqesMut nt _
~~~~~~%plaques % plaques
10 108 7.3 ± 0.8 23.3 ± 1.2
100 108 13.9±1.3 14.3±1.4
1000 1 109 18.0 ± 1.7 20.4 ± 1.7
Plaques containing mutant standard or wild-type sequence at the Pvull recognition sequence (# 1727 - 1732).
Phage trom at least 2 packagings were used and plaques on 10.15 petri dishes were analysed.
Figure 3. Analysis of X-plaques for base-pair mutations in PvuII-recognition
sequence 1727- 1732 of c-Ha-rasl Mixtures of a few copies of mutant standard
pSP64-ras PvuIISt with 108 copies of wild-type pSVneo-ras were processed by
the RFLP/PCR protocol described in 'Methods'. The amplification product was
cloned into XgtlO, plaques transferred to plaque screens and analyzed by
hybridization with 3-P-end-labeled mutant oligonucleotide probes for Taq-
polymerase induced single bp mutations in the PvuII recognition sequence
1727-1732. The selectivity of the washing conditions was ascertained for each
mutation with authentic mutant constructs. Upper half, left-side: plaques containing
authentic mutant CACCTG; right-side: plaques on 4 plates with same mutation
originating from the amplification mixture. Lower half, left-side: plaques containing
authentic mutant CAGGTG; right-side: plaques on 4 plates with the same mutation
originating from the amplification mixture.
of wt-sequence giving rise to 7.3% of total plaques. Increasing
initial copy numbers of Pvull mutant standard gave rise to larger
fractions of plaques containing the mutant standard sequence. The
fractions of wt-plaques varied from 14 to 23%.
Taq-polymerase errors in Pvul-site 1727-1732 of c-Ha-rasl
Despite exhaustive restriction with PvuII before and during
amplification a small amount of intact wt-sequences undoubtedly
remains, will be amplified and can give rise to Taq-polymerase
errors. Amplified sequences containing Taq-polymerase errors
in the PvuII recognition sequence 1727- 1732 are resistant to
digestion and will be cloned. The ultimate sensitivity of the
RFLP/PCR method for a particular bp in the chosen recognition
site depends on the error-rate of Taq-polymerase for the
replication of this bp. Therefore, we probed X-plaques resulting
from the mixtures of mutant standard with excess wt-sequence
for their content of Taq-polymerase induced single bp changes
in the internal tetranucleotide AGCT of the PvuII recognition
sequence. The plaques were probed with specific oligonucleotides
for all 12 possible mutations. Figure 3 shows an example in which
discs had been probed for a G- C transversion giving rise to
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1 copy Pvu II mutant standard: TGGT
109 copies wild - type: AGCT
10 copies Pvu II mutant standard: TGGT
108 copies wild - type: AGCT
100 copies Pvu II mutant standard: TGGT
10 8 copies wild - type: AGCT
CGCT A >C
AGCG T -G
AGCA T )A
TGCT A T
AACT G-A
GGCT A--G
AGTT C -T
AGCC T -C
ACCT G-C
ATCT G-T
AGAT C -A
AGGT C--G *
TGGT St
0 10 20 0 10 20 0 10 20
PERCENT LAMBDA PLAQUES
Figure 4. Spectrum of Taq-polymerase induced base-pair mutations in the Pvull-site 1727-1732 of exon 1 of c-Ha-rasl. Mixtures of a few copies of mutant standard
pSP64-ras PvulISt with 10 or 109 copies of wild-type pSVneo-ras were processed by the RFLP/PCR protocol as described in 'Methods'. X-plaques were transferred
onto plaque screens and analyzed for their content of all 12 possible bp mutations in the internal tetranucleotide AGCT of the PvuIl- recognition sequence by hybridization
with 2-P-end-labeled oligonucleotide probes. The results represent means from two X-packagings and 10-15 petri dishes containing 100-200 plaques for each
experimental condition. The selectivity of the conditions for each probe was ascertained with authentic mutant constructs. Individual plaques only hybridized with
a single probe (see 'Methods').
CACCTG occurring with moderate frequency (upper portion)
and a C-G transversion giving rise to CAGGTG which
represents a frequent Taq-induced mutation in the Pvull site
(lower portion). In all cases the specificity of the probing
conditions was ascertained with mixtures of authentic mutant
constructs and by assuring that each plaque only hybridized with
a single oligonucleotide probe.
Figure 4 compares the frequencies of the 12 possible Taq-
polymerase induced bp changes at the internal tetranucleotide A-
GCT of the Pvul-site in 3 independent amplification experiments
in which 109 (Figure 4A) and 108 initial copies of wt pSVneo-
rasl (Figure 4B & C) were used, respectively. While there are
small quantitative differences the following consensus can be
reached for the relative abundance of Taq-induced errors:
C-A(AGAT) _ C-G(AGGT)>G-T(ATCT). Since the
amount of wt-copies which remain undigested during the
amplification cycles is not known absolute Taq-error frequencies
cannot be derived from our data. In contrast, from a comparison
to the data with the mutant standard it is evident that less than
10 copies containing a single bp mutation in the presence of 109
copies of wt-sequence can readily be detected for mutations with
low Taq-error frequencies, e.g. for A-C(CGCT); T-G(A-
GCG); T-A(AGCA); A-T(TGCT); G-A(AACT).
Rescue of a single base pair mutation in MspI-site 1695-1698
from excess wild-type c-Ha-rasl DNA
The rescue of mutant standard such as pSP64-ras PvullSt with
multiple bp changes in a chosen restriction site from excess wt
sequences is not affected by Taq-polymerase errors. In contrast,
the sensitivity of the detection of single bp mutations is limited
by polymerase errors originating from the amplification of
residual undigested wt sequences. We assessed the capacity of
the RFLP/PCR protocol to rescue a few copies of the c-Ha-rasl
exon 1 fragment 1646-1784 containing a G- T transversion at
residue 1698 which is part of the MspI-site 1695-1698 from
a large excess of wt c-Ha-rasl DNA. The chosen mutation affects
the middle bp of codon 12 and was detected in the c-Ha-rasl
gene of the EJ human bladder carcinoma line (8) (see Figure 1
for sequence information). Three samples were analyzed by
RFLP/PCR (1) 108 copies of exhaustively MspI/HpalI digested
wt pSVneo-rasl (2) 100 copies mutant pSP64-rasl-T1698
(XbaI/EcoRI restricted) plus 108 copies MspI/HpaII digested
pSVneo-ras (3) 1000 copies mutant pSP64-rasl-T1698
(XbaI/EcoRI restricted) plus 108 copies MspI/HpaII digested
pSVneo-rasl. The samples were amplified with repeated MspI
restrictions in 35 cycles with 'non-clonable' amplimers and 10
final cycles with amplimers containing tails with EcoRI
recognition sequences (see Figure 1 and Methods). The amplified
136 bp fragments were cloned into XgtlO and plaques analyzed
by hybridization with 20-mer oligonucleotides corresponding to
the wt c-Ha-rasl sequence 1688-1707 and with the mutant
sequence containing a T-residue at position 1698. From the results
shown in Figure 5 it is evident that Taq-polymerase amplification
of residual wt ras I DNA which escaped restriction at the MspI-
site 1695-1698 generated 12% X-plaques with G-T
transversions at residue 1698 for the sample containing only 108
copies of pSVneo-rasl at the outset. The percentage of plaques
containing G-T transversions at residue 1698 was 23% for the
initial mixture of 100 copies mutant pSP64-rasl-T1698 with 108
copies of wt pSVneo-rasl corresponding to a 2 fold increase over
AGCG T -G *
CGGT A >C t
TGCT A >T*
H
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Figure 5. Rescue of a single base pair mutation in the MspI-site 1695-1698
of c-Ha-rasl from excess wild type DNA. Three samples of c-Ha-rasl DNA
were analyzed by the RFLP/PCR protocol for mutations in the MspI-site
1695-1698: (1) 108 copies of exhaustively MspI/HpaII digested pSVneo-rasl
(2) 100 copies of mutant pSP64-rasl-T1698 (xbal/EcoRI digested) plus 108
copies MspI/HpaII digested pSVneo-rasl (3) 1000 copies mutant
pSP64-rasl-T1698 (XbaI/EcoRI digested)plus 108 copies MspI/HpaII digested
pSVneo-rasl. The conditions for amplification, cloning of the amplified fragments
into XgtlO and analysis of plaques by hybridization with 32P-end-labeled wt- and
mutant (T1698) oligonucleotide probes are described under 'Methods'. Results
are derived from 2 independent packagings and 600-1100 plaques on 4-6 Petri
dishes. Error bars represent standard deviations.
the fraction produced by Taq-polymerase infidelity. At 1000
initial copies of mutant pSP64-rasl-T1698 plus 108 copies wt
pSVneo-rasl the percentage of mutant plaques had increased to
34%. The Figure also gives the percentage of plaques which
contained wt-sequence 1688-1707.
DISCUSSION
The aim of the present work was to test the feasibility to use
the RFLP/PCR approach for the development of a genotypic
mutation system. Such a system should be capable of measuring
low frequency mutations in any gene of known sequence without
the need for the phenotypic selection of mutated cells (6). In the
RFLP/PCR approach wt-sequences are selectively removed by
exhaustive restriction and resistant sequences are amplified by
PCR. We have chosen the tetranucleotide AGCT of PvuII
recognition site for our studies because it contains all 4
nucleotides. While the composition of the PCR product reflects
the initial mixture of mutations it does not allow the estimation
of absolute mutation frequencies. Therefore, we are using an
internal 'mutant standard' for calibration. We have constructed
a mutant standard with 2bp changes in Pvull recognition site and
a third mutation upstream. This allows the distinction between
X-plaques containing mutant standard from plaques containing
single bp mutations in the final analysis with specific probes. In
the present experiments we have used the mutant standard
pSP64-ras PvullSt to evaluate the capacity of the RFLP/PCR
protocol to rescue a few copies of mutated sequences in the PvuIl
site 1727-1732 from a large excess of wt c-Ha-rasl without
interference by Taq-polymerase errors. We have ascertained that
mutant standard and wt-sequences are amplified with equal
efficiencies (see Figure 2). Our results indicate (Table 1) that
10 copies of mutant standard were readily rescued from 108 to
109 copies of wt-DNA. While the fraction of mutant standard
plaques increased with increasing copy number there is no simple
relationship between the two parameters.
In contrast to the rescue of mutant standard the sensitivity of
the detection of single bp mutations depends on the frequency
of polymerase errors during the replication of a particular bp.
Only polymerase errors originating from wt-sequences will
interfere since errors in already mutated sequences will give rise
to double mutations which are not detected with oligonucleotide
probes containing a single altered base. Therefore, the final
polymerase error frequencies will depend on the completeness
of the removal of wt-sequences by restriction and our protocol
employs several steps of restriction before and during
amplification. We used conditions for the amplification reaction
which were expected to yield relatively low Taq-polymerase
errors (10) but retained high amplification efficiency, i.e. Mg2+
concentration of 6.7 mM, a total concentrations of dNTPs of 4
mM but a relatively high pH of 8.2 (70°C). The data in Figure 4
attests to the large differences in Taq-polymerase errors
depending on the type of bp and the sequence. The replication
of G.C bp produced more errors then the replication of A.T bp
and transversions were considerably more frequent than
transitions. Sequence dependence is indicated by the fact that the
C-G transversion (AGGT) was more frequent than the G-C
transversion (ACCT) and the C-A transversion (AGAT) more
frequent than the G- T transversion (ATCT). Comparison of
the three panels in Figure 4 indicates that the fraction of plaques
with Taq-polymerase errors did not change significantly when
the initial number of wt-copies was increased from 108 to 109.
Under the latter conditions a single copy of mutant standard
resulted in 0.3% mutant standard plaques. We estimate that at
best RFLP/PCR analysis at PvuII-site 1727- 1732 is capable of
rescueing 1-5 copies of a single bp mutation from 109 copies
of c-Ha-rasl for mutations with low Taq-polymerase error
frequencies, e.g. for A-C (CGCT), T-G (AGCG), A-T
(TGCT) and T-A (AGCA). It is conceivable that polymerase
errors can be further reduced by modifying the amplification
conditions (10,11) and consequently that the sensitivity of our
RFLP/PCR protocol can be increased.
We have further assessed the sensitivity of the RFLP/PCR
protocol for the rescue of a single bp mutation in the MspI-site
1695- 1698 of exon 1 of c-Ha-rasl . Unlike the rescue of a doubly
mutated standard such as pSP64-ras PvullSt the capacity to rescue
a single bp mutation is limited by backgrounds caused by
polymerase errors. The experimental conditions were analogous
to the PvuII-site 1727-1732 with the exception that nested
'clonable' left-side amplimer was used for the final 10 PCR
cycles. The chosen mutant results from a G-T transversion at
bp 1698 which represents the middle bp of codon 12. Mutations
in this ras-codon are frequently detected in the DNA from human
tumor tissues (1) and the particular G-T transversion studied
in the present work had been first detected in the EJ human
bladder carcinoma line (8). Our results show that 100 copies of
a rasl fragment containing a mutated MspI-site 1695-1698 with
a T-residue in position 1698 could be readily rescued from 108
copies of wt rasI DNA. As expected from the analysis of the
PvuH-site 1727- 1732 under similar experimental conditions the
G -T transversion at bp 1698 represents a relatively frequent
Taq-polymerase error. The fraction of plaques containing the
T1698 mutation was 12% for the sample composed initially of
only wt DNA. This value is comparable to 11% for the frequency
of Taq-polymerase induced G-T transversions at bp 1729 in
the Pvull-site 1727- 1732 for the sample containing initially only
1 copy of PvuII mutant standard but 109 copies of wt ras 1
DNA.
The predominance of transversions involving G.C bp in our
experiments disagrees with published work in which A.T. -G.C
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transitions were reported to be the most frequent Taq-polymerase
errors (10,11,12,13). Differences in the amplification conditions
may be responsible for these discrepancies; e.g. high ratios of
concentrations of Mg2+/total dNTPs in several published reports
relative to a ratio of 1.7 in the present work; the use of relatively
high concentrations ofDMSO in our work in contrast to previous
authors etc.. It should be stressed that our data does not allow
it to calculate absolute error-frequencies for Taq-polymerase
because the amount of residual, unrestricted wt-sequence in the
amplification mixture cannot be assessed by the RFLP/PCR
protocol.
In conclusion, the RFLP/PCR protocol described here allows
the analysis of point mutations (bp-changes, small deletions and
insertions) in any gene of known sequence without the need to
select mutated cells on the basis of an altered phenotype. The
method is highly sensitive and relatively simple but limited to
mutations which result in the elimination of a restriction site. The
experimental design of the RFLP/PCR approach to genotypic
mutation analysis has been discussed previously (14,15).
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